HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development.
HIV
Lessons
Research
SARS-COV-2
Vaccine
Journal
Current HIV/AIDS reports
ISSN: 1548-3576
Titre abrégé: Curr HIV/AIDS Rep
Pays: United States
ID NLM: 101235661
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
accepted:
09
12
2021
pubmed:
29
1
2022
medline:
15
3
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
This review examines the major advances and obstacles in the field of HIV vaccine research as they pertain to informing the development of vaccines against SARS-CoV-2. Although the field of HIV research has yet to deliver a licensed vaccine, the technologies developed and knowledge gained in basic scientific disciplines, translational research, and community engagement have positively impacted the development of vaccines for other viruses, most notably and recently for SARS-CoV-2. These advances include the advent of viral vectors and mRNA as vaccine delivery platforms; the use of structural biology for immunogen design; an emergence of novel adjuvant formulations; a more sophisticated understanding of viral phylogenetics; improvements in the development and harmonization of accurate assays for vaccine immunogenicity; and maturation of the fields of bioethics and community engagement for clinical trials conducted in diverse populations. Decades of foundational research and investments into HIV biology, though yet to yield an authorized or approved vaccine for HIV/AIDS, have now paid dividends in the rapid development of safe and effective SARS-CoV-2 vaccines. This latter success presents an opportunity for feedback on improved pathways for development of safe and efficacious vaccines against HIV and other pathogens.
Identifiants
pubmed: 35089535
doi: 10.1007/s11904-021-00597-4
pii: 10.1007/s11904-021-00597-4
pmc: PMC8795326
doi:
Substances chimiques
AIDS Vaccines
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-93Informations de copyright
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Références
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Protein Cell. 2018 Jul;9(7):596-615
pubmed: 29667004
Science. 2013 Dec 20;342(6165):1484-90
pubmed: 24179160
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
JCI Insight. 2020 Jan 30;5(2):
pubmed: 31996483
Curr Opin Immunol. 2020 Aug;65:50-56
pubmed: 32387642
J Infect Dis. 2006 Dec 15;194(12):1661-71
pubmed: 17109337
J Virol. 2015 Aug;89(15):7478-93
pubmed: 25972551
PLoS Pathog. 2015 Aug 12;11(8):e1005101
pubmed: 26267144
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
Cold Spring Harb Perspect Biol. 2017 Nov 1;9(11):
pubmed: 28159876
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Lancet. 2018 Jul 21;392(10143):232-243
pubmed: 30047376
Vaccine. 2015 Oct 13;33(42):5578-5587
pubmed: 26372857
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9
pubmed: 25681373
Lancet. 2012 Jul 28;380(9839):314-6
pubmed: 22819655
J Infect Dis. 2017 Apr 15;215(8):1255-1263
pubmed: 28329190
Science. 2002 Jun 28;296(5577):2354-60
pubmed: 12089434
Health Aff (Millwood). 2021 Jan;40(1):33-41
pubmed: 33211554
PLoS One. 2013;8(1):e53629
pubmed: 23349725
Expert Opin Drug Deliv. 2016 Jun;13(6):807-16
pubmed: 26866300
PLoS One. 2016 Jan 04;11(1):e0145637
pubmed: 26727218
Biochim Biophys Acta. 2015 Mar;1848(3):775-80
pubmed: 25511587
Immunol Rev. 2017 Jan;275(1):161-182
pubmed: 28133806
Nat Rev Drug Discov. 2014 Oct;13(10):759-80
pubmed: 25233993
Vaccine. 2021 Dec 17;39(51):7394-7400
pubmed: 34815117
Science. 1990 Mar 23;247(4949 Pt 1):1465-8
pubmed: 1690918
Vaccine. 2010 Oct 8;28(43):7016-24
pubmed: 20728522
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
Pharm Res. 1995 Oct;12(10):1439-46
pubmed: 8584477
PLoS One. 2012;7(7):e40385
pubmed: 22808149
Science. 2015 Jul 10;349(6244):aac4223
pubmed: 26089353
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23652-23662
pubmed: 32868447
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Virology. 2008 Jun 5;375(2):315-20
pubmed: 18367229
PLoS One. 2015 Jun 22;10(6):e0128779
pubmed: 26098893
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
J Virol. 2013 Feb;87(3):1708-19
pubmed: 23175374
J Infect Dis. 2005 Mar 1;191(5):654-65
pubmed: 15688278
PLoS Med. 2007 Dec;4(12):e348
pubmed: 18052607
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
Science. 2013 May 31;340(6136):1113-7
pubmed: 23618766
Lancet. 2020 May 2;395(10234):1405-1406
pubmed: 32243778
EBioMedicine. 2018 Mar;29:146-154
pubmed: 29519670
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2013 Dec 20;342(6165):1477-83
pubmed: 24179159
J Virol. 2020 Jan 31;94(4):
pubmed: 31776278
Nat Commun. 2015 Sep 03;6:8143
pubmed: 26333350
Cell Host Microbe. 2018 Jul 11;24(1):25-33
pubmed: 30001521
Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4
pubmed: 33306985
Science. 2015 Jul 17;349(6245):320-4
pubmed: 26138104
Lancet Infect Dis. 2012 Jul;12(7):531-7
pubmed: 22652344
N Engl J Med. 2021 Apr 8;384(14):1281-1283
pubmed: 33830709
J Infect Dis. 2016 Jun 15;213(12):1946-54
pubmed: 26908741
PLoS Pathog. 2017 Feb 24;13(2):e1006182
pubmed: 28235027
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864
Nat Struct Mol Biol. 2016 Sep;23(9):811-820
pubmed: 27478931
J Immunol. 2015 Aug 1;195(3):994-1005
pubmed: 26116502
Annu Rev Med. 2019 Jan 27;70:91-104
pubmed: 30691364
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Curr Opin Microbiol. 2000 Oct;3(5):445-50
pubmed: 11050440